CLOs on the Move

Emergent BioSolutions

www.emergentbiosolutions.com

 
Emergent BioSolutions is a global life sciences company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases.
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details
Jeannett Jackman
Director, Ethics and Compliance Profile
Ellen Rice
Head of Global Employment Law and Litigation Profile
Jennifer Fox
SVP Legal Affairs and Deputy General Counsel Profile

Jobs

VP, Chief Information Security Officer

Emergent BioSolutions Remote
Details here:
https://careers.emergentbiosolutions.com/job/Gaithersburg-Vice-President%2C-Chief-Information-Security-Officer-Remote-MD-20879/1200080000/?feedId=306800&utm_source=Indeed&utm_campaign=EmergentBio_Indeed&jobPipeline=Indeed

Similar Companies

Viridian Therapeutics

Viridian Therapeutics focuses in advancing new treatments for patients with diseases that are underserved by today`s therapies.

Radford Surveys Consulting

Radford Surveys Consulting is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mirus Bio

Mirus Bio is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oxford Immunotec

Oxford Immunotec is a global, commercial-stage diagnostics company committed to improving patient care by providing advanced, innovative tests in the field of immunology. Our proprietary   T-SPOT technology platform allows us to measure the responses of specific immune cells, known as T cells, to inform the diagnosis, prognosis and monitoring of patients with immunologically controlled diseases.   The initial product we have developed using our T-SPOT technology platform is our T-SPOT.TB test, which is used to test for latent Tuberculosis (TB) infection, or LTBI. Our T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where we have received pre-market approval (PMA) from the Food and Drug Administration (FDA), in Europe, where we have obtained a CE mark, as well as Japan and China. Our T-SPOT.TB test has been included in clinical guidelines (that is, guidelines issued by governmental agencies and professional societies covering recommended or suggested uses of available diagnostics) for TB screening in 17 countries, including the United States, several European countries and Japan.   We are a publicly traded company listed in the United States on the NASDAQ stock exchange (NASDAQ:OXFD).

Clario

Clario is a leading healthcare research and technology company that generates the richest clinical evidence in the industry for our pharmaceutical, biotech and medical device partners. Across decentralized, hybrid and site-based trials, our deep scientific expertise, global scale and the broadest endpoint technology platform in the industry allows our partners to transform lives. Clario has the only technology platform that combines eCOA, cardiac safety, medical imaging, precision motion, and respiratory endpoints. Clario`s global team of science, technology and operational experts have helped deliver more than 27,000 trials and contributed to over 500 FDA and EMEA new drug approvals involving more than seven million participants in over 100 countries. Our innovation has been transforming clinical trials for 50 years.